Free Trial
NASDAQ:CYTK

Cytokinetics (CYTK) Stock Price, News & Analysis

Cytokinetics logo
$35.25 +0.11 (+0.31%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$35.75 +0.50 (+1.42%)
As of 08/7/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cytokinetics Stock (NASDAQ:CYTK)

Key Stats

Today's Range
$34.67
$35.59
50-Day Range
$30.88
$38.89
52-Week Range
$29.31
$59.39
Volume
1.04 million shs
Average Volume
1.26 million shs
Market Capitalization
$4.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.92
Consensus Rating
Moderate Buy

Company Overview

Cytokinetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

CYTK MarketRank™: 

Cytokinetics scored higher than 82% of companies evaluated by MarketBeat, and ranked 165th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cytokinetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cytokinetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytokinetics are expected to decrease in the coming year, from ($5.24) to ($5.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytokinetics is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytokinetics is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cytokinetics' valuation and earnings.
  • Percentage of Shares Shorted

    13.64% of the float of Cytokinetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytokinetics has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Cytokinetics has recently increased by 6.06%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cytokinetics does not currently pay a dividend.

  • Dividend Growth

    Cytokinetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.64% of the float of Cytokinetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytokinetics has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Cytokinetics has recently increased by 6.06%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cytokinetics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Cytokinetics this week, compared to 10 articles on an average week.
  • Search Interest

    Only 3 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,350,617.00 in company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Cytokinetics is held by insiders.

  • Read more about Cytokinetics' insider trading history.
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Raymond James downgrades Cytokinetics (CYTK) to a Hold
Cytokinetics Merits A Speculative Buy Rating
See More Headlines

CYTK Stock Analysis - Frequently Asked Questions

Cytokinetics' stock was trading at $47.04 on January 1st, 2025. Since then, CYTK stock has decreased by 25.1% and is now trading at $35.25.

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its earnings results on Thursday, August, 7th. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.20. The firm's revenue was up 26727.3% on a year-over-year basis.
Read the conference call transcript
.

Cytokinetics' top institutional investors include Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. (0.91%), Aberdeen Group plc (0.77%), TD Asset Management Inc (0.46%) and E. Ohman J or Asset Management AB (0.34%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, John T Henderson, Andrew Callos, Edward M Md Kaye, Wendall Wierenga, Muna Bhanji, B Lynne Parshall, Robert Wong and Robert Arthur Harrington.
View institutional ownership trends
.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and GE Aerospace (GE).

Company Calendar

Last Earnings
5/06/2025
Today
8/07/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYTK
CIK
1061983
Employees
250
Year Founded
1997

Price Target and Rating

High Price Target
$120.00
Low Price Target
$41.00
Potential Upside/Downside
+101.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$589.53 million
Net Margins
-3,201.47%
Pretax Margin
-3,201.47%
Return on Equity
N/A
Return on Assets
-43.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.99
Quick Ratio
5.99

Sales & Book Value

Annual Sales
$19.22 million
Price / Sales
219.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.15) per share
Price / Book
-30.65

Miscellaneous

Outstanding Shares
119,427,000
Free Float
116,202,000
Market Cap
$4.21 billion
Optionable
Optionable
Beta
0.64

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:CYTK) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners